Biliary Neoplasia

Biliary neoplasia refers to a diverse group of primary and metastatic tumors arising from the epithelial lining of the intrahepatic or extrahepatic bile ducts, the gallbladder, or the peri-biliary glands. These neoplasms can be benign (e.g., biliary adenoma, cystadenoma) or malignant (e.g., cholangiocarcinoma, gallbladder adenocarcinoma). Cholangiocarcinoma is the most common primary malignant tumor of the biliary system in dogs and cats, accounting for approximately 1-2% of all canine tumors and up to 5% of feline tumors. Biliary neoplasia can cause extrahepatic bile duct obstruction, cholecystitis, cholelithiasis, and hepatic dysfunction. The disease may be localized, multifocal, or diffusely infiltrative, and metastasis to regional lymph nodes, liver, lungs, and peritoneum is common in malignant forms. Clinical presentation is often insidious, with non-specific signs such as lethargy, anorexia, vomiting, and weight loss. Early diagnosis is challenging due to the lack of specific clinical signs and the deep anatomical location of the biliary tree. Advanced imaging (ultrasonography, CT, MRI) and histopathology are essential for definitive diagnosis and staging. Prognosis is generally poor for malignant biliary neoplasia, with median survival times of weeks to months, whereas benign tumors may be cured by surgical resection.

The exact etiology of biliary neoplasia in dogs and cats is largely unknown, but several risk factors and potential causative agents have been proposed. Chronic inflammation of the biliary tract (cholangitis, cholangiohepatitis) is considered a predisposing factor, as chronic inflammation can lead to cellular proliferation and neoplastic transformation. In cats, chronic lymphocytic cholangitis has been associated with the development of cholangiocarcinoma. Infectious agents, such as liver flukes (e.g., Platynosomum fastosum in cats, Opisthorchis viverrini in humans), have been implicated in the pathogenesis of cholangiocarcinoma in endemic areas, but their role in domestic pets is less clear. Exposure to environmental carcinogens, such as aflatoxins (produced by Aspergillus species) and nitrosamines, has been linked to hepatocellular and biliary tumors in animals. Genetic mutations, including alterations in oncogenes (e.g., KRAS, TP53) and tumor suppressor genes, are likely involved, but specific mutations have not been fully characterized in veterinary medicine. In dogs, biliary cystadenomas may arise from congenital or acquired bile duct hamartomas. No viral etiology has been confirmed in domestic species, although retroviruses have been implicated in experimental models. Overall, the etiology is likely multifactorial, involving genetic predisposition, chronic inflammation, and environmental exposures.

Biliary neoplasia is uncommon in dogs and cats. Cholangiocarcinoma accounts for approximately 1-2% of all canine tumors and up to 5% of feline tumors. In dogs, the mean age at diagnosis is 10-12 years, with no strong breed predisposition, although some reports suggest a higher incidence in Labrador Retrievers, Golden Retrievers, and Shetland Sheepdogs. In cats, the mean age is 10-12 years, and domestic shorthair cats are overrepresented. There is no significant sex predilection in either species. Biliary adenomas and cystadenomas are more common in older dogs and cats, often found incidentally during abdominal imaging or necropsy. Geographic variation may exist, with higher incidence in regions where liver flukes are endemic, but this is not well-documented in pets. No seasonal pattern has been reported. The prevalence of metastatic disease at the time of diagnosis is high, with up to 80% of malignant biliary tumors having metastasized to regional lymph nodes, liver, lungs, or peritoneum. Early detection is rare due to the non-specific clinical signs and the lack of routine screening in asymptomatic animals.

The pathophysiology of biliary neoplasia involves the malignant transformation of biliary epithelial cells, leading to uncontrolled proliferation, invasion, and metastasis. The neoplastic cells can arise from the intrahepatic bile ducts, extrahepatic bile ducts, or gallbladder. As the tumor grows, it can cause mechanical obstruction of the bile ducts, leading to cholestasis, which is characterized by the accumulation of bile acids, bilirubin, and cholesterol in the liver and systemic circulation. Cholestasis results in icterus, elevated serum alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and bilirubin. Chronic cholestasis can lead to secondary biliary cirrhosis, portal hypertension, and hepatic failure. The tumor may also invade the gallbladder wall, causing cholecystitis, cholelithiasis, or gallbladder rupture, leading to bile peritonitis. Malignant tumors have a high propensity for local invasion into the liver parenchyma and adjacent tissues, as well as lymphatic and hematogenous spread. Metastasis to the lungs, peritoneum, and other organs is common. The tumor can also induce a paraneoplastic syndrome, such as hypoglycemia or hypercalcemia, though these are rare. The systemic inflammatory response to the tumor can cause cachexia, anorexia, and weight loss. The molecular mechanisms involve dysregulation of cell cycle control, apoptosis, and angiogenesis, with overexpression of growth factors and their receptors, such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF).

Predisposing factors for biliary neoplasia include chronic inflammatory diseases of the biliary tract, such as cholangitis and cholangiohepatitis, which are more common in cats. In cats, chronic lymphocytic cholangitis has been associated with an increased risk of cholangiocarcinoma. Liver fluke infections, particularly Platynosomum fastosum in cats, can cause chronic biliary inflammation and are considered a risk factor in endemic areas. Exposure to environmental toxins, such as aflatoxins from contaminated food, and nitrosamines may increase the risk. Genetic predisposition is suspected, but specific breeds have not been definitively identified. Age is a significant risk factor, with older animals (over 10 years) being more commonly affected. Obesity and high-fat diets may contribute to the development of gallbladder disease, but their direct link to neoplasia is unclear. Immunosuppression, whether due to chronic disease or drug therapy, may also play a role. In dogs, biliary cystadenomas may be associated with congenital anomalies of the bile ducts. Overall, the presence of chronic biliary inflammation appears to be the most significant predisposing factor.

Clinical signs of biliary neoplasia are often non-specific and may be absent in early stages. Common signs include lethargy, anorexia, weight loss, vomiting, and diarrhea. Icterus (jaundice) is a prominent sign when extrahepatic bile duct obstruction occurs, and it may be accompanied by dark urine and pale feces. Abdominal distension may be noted due to hepatomegaly, ascites, or a palpable abdominal mass. Fever may be present if there is concurrent cholangitis or cholecystitis. In cases of gallbladder rupture, acute abdomen, shock, and peritonitis may develop. Chronic cases may present with signs of hepatic encephalopathy, such as behavioral changes, disorientation, and seizures, due to portosystemic shunting or hepatic failure. Paraneoplastic syndromes, such as hypoglycemia, may cause weakness, tremors, or collapse. In cats, clinical signs may be more subtle, with weight loss and poor coat condition being prominent. Physical examination may reveal icteric mucous membranes, hepatomegaly, and a cranial abdominal mass. Ascites may be present in advanced cases. The clinical signs can be categorized by stage: peracute (e.g., acute bile peritonitis), acute (e.g., extrahepatic obstruction), subacute (e.g., progressive weight loss), chronic (e.g., hepatic failure), and terminal (e.g., severe cachexia, coma).

Differential diagnoses for biliary neoplasia include: 1) Cholecystitis (bacterial or sterile) - presents with similar signs of abdominal pain, fever, and icterus; ultrasonography may show gallbladder wall thickening, sludge, or gallstones, but no mass; cytology and culture of bile can confirm infection. 2) Cholelithiasis - can cause extrahepatic bile duct obstruction; imaging shows hyperechoic foci with acoustic shadowing; no mass lesion. 3) Extrahepatic bile duct obstruction due to pancreatitis - history of pancreatitis, elevated lipase, and imaging findings of pancreatic inflammation; no biliary mass. 4) Hepatic neoplasia (e.g., hepatocellular carcinoma) - may present with similar signs; imaging shows a liver mass, but histopathology is needed to differentiate. 5) Cholangiohepatitis - chronic inflammation of the biliary tree; liver enzymes elevated, but no mass; biopsy shows inflammatory infiltrate. 6) Gallbladder mucocele - in dogs, can cause obstruction; ultrasonography shows a characteristic 'kiwi' pattern; no neoplastic cells. 7) Biliary cystadenoma - benign tumor; imaging shows cystic mass, but histopathology is required for definitive diagnosis. 8) Metastatic disease to the liver - primary tumor elsewhere; imaging may show multiple nodules; biopsy and staging are needed. 9) Hepatic abscess - fever, leukocytosis, and imaging shows cavitary lesion; culture and cytology confirm infection. 10) Feline infectious peritonitis (FIP) - in cats, can cause icterus and abdominal effusion; coronavirus serology and histopathology are diagnostic. Key features that rule in biliary neoplasia include the presence of a mass lesion in the biliary tree or gallbladder, progressive icterus, and histopathological confirmation of neoplastic cells.

The diagnostic algorithm for biliary neoplasia begins with a thorough history and physical examination, with particular attention to icterus, abdominal palpation, and signs of hepatic disease. Initial laboratory tests include a complete blood count (CBC), serum biochemistry profile, and urinalysis. If cholestasis is suspected, serum bile acids and bilirubin are measured. Abdominal ultrasonography is the next step, as it is highly sensitive for detecting biliary masses, gallbladder wall thickening, bile duct dilation, and extrahepatic obstruction. If a mass is identified, fine-needle aspiration (FNA) with cytology may be performed, but it has limited sensitivity for differentiating benign from malignant lesions. For a definitive diagnosis, histopathology via ultrasound-guided biopsy, laparoscopic biopsy, or surgical biopsy is required. Advanced imaging, such as computed tomography (CT) or magnetic resonance imaging (MRI), may be used for staging and surgical planning. If extrahepatic bile duct obstruction is present, endoscopic retrograde cholangiopancreatography (ERCP) may be considered in specialized centers. Thoracic radiographs or CT are recommended to rule out pulmonary metastasis. If ascites is present, abdominocentesis with fluid analysis and cytology can help identify neoplastic cells or bile peritonitis. The diagnostic algorithm should be stepwise, starting with non-invasive tests and progressing to invasive procedures as needed.

Laboratory findings in biliary neoplasia are consistent with cholestasis and hepatic dysfunction. Hematology may show a mild to moderate leukocytosis due to inflammation or infection, and anemia may be present in chronic cases. Serum biochemistry typically reveals elevated alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT), which are sensitive indicators of cholestasis. Total bilirubin is often elevated, with a conjugated (direct) hyperbilirubinemia. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) may be mildly to moderately elevated due to hepatocellular damage secondary to cholestasis or tumor invasion. Serum bile acids are increased, especially post-prandially. Hypoalbuminemia may occur due to chronic liver disease or malnutrition. Coagulation abnormalities, such as prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), may be present due to vitamin K malabsorption or hepatic dysfunction. Urinalysis may show bilirubinuria, which is an early indicator of cholestasis. Blood gas analysis may reveal metabolic acidosis if there is concurrent sepsis or peritonitis. Specific biomarkers, such as cancer antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA), have been evaluated in humans but are not routinely used in veterinary medicine. In cats, feline pancreatic lipase immunoreactivity (fPLI) may be elevated if there is concurrent pancreatitis. Serology and PCR for infectious agents (e.g., liver flukes, FIP) may be performed if infectious causes are suspected.

Imaging plays a crucial role in the diagnosis and staging of biliary neoplasia. Abdominal radiography may show hepatomegaly, a soft tissue mass in the cranial abdomen, or, rarely, mineralization within the tumor. However, radiography is not sensitive for biliary masses. Abdominal ultrasonography is the primary imaging modality. Findings may include a mass lesion in the liver or gallbladder, thickening of the gallbladder wall, dilation of the intrahepatic or extrahepatic bile ducts, and the presence of a distended gallbladder. The mass may be hypoechoic, hyperechoic, or mixed echogenicity, and may have a heterogeneous appearance. Doppler ultrasonography can assess vascular invasion. Ultrasonography can also detect extrahepatic bile duct obstruction by identifying a dilated common bile duct and a distended gallbladder. However, ultrasonography cannot definitively differentiate benign from malignant lesions. Computed tomography (CT) provides more detailed anatomical information and is superior for staging, as it can detect pulmonary metastasis and abdominal lymphadenopathy. CT angiography can evaluate vascular invasion. Magnetic resonance imaging (MRI) offers excellent soft tissue contrast and is useful for evaluating the biliary tree, especially with magnetic resonance cholangiopancreatography (MRCP). Endoscopic retrograde cholangiopancreatography (ERCP) is an advanced technique that allows direct visualization and biopsy of the biliary tree, but it is not widely available in veterinary practice. Thoracic radiography or CT is essential to rule out pulmonary metastasis. In cases of ascites, abdominal ultrasonography can guide abdominocentesis.

Cytology and histopathology are essential for definitive diagnosis of biliary neoplasia. Fine-needle aspiration (FNA) of a biliary mass can be performed under ultrasound guidance. Cytological examination may reveal clusters of epithelial cells with variable atypia, including anisocytosis, anisokaryosis, prominent nucleoli, and high nuclear-to-cytoplasmic ratio. However, cytology has limited sensitivity and specificity for differentiating benign from malignant biliary tumors, as well-differentiated cholangiocarcinoma may resemble normal biliary epithelium. Histopathology is the gold standard. Biopsy samples can be obtained via ultrasound-guided core biopsy, laparoscopic biopsy, or surgical biopsy. Histological features of cholangiocarcinoma include tubular or acinar structures lined by atypical epithelial cells, desmoplastic stroma, and invasion into surrounding tissue. Biliary adenomas are well-circumscribed, non-invasive proliferations of benign biliary epithelium. Cystadenomas are characterized by multiple cystic spaces lined by cuboidal to columnar epithelium. Immunohistochemistry (IHC) can be used to confirm the biliary origin of the tumor, with positive staining for cytokeratin 7 (CK7) and cytokeratin 19 (CK19). Special stains, such as mucicarmine, may highlight mucin production. Histopathology also provides information on tumor grade, mitotic index, and the presence of vascular invasion, which are important prognostic factors.

Treatment of biliary neoplasia depends on the tumor type, stage, and the presence of complications such as extrahepatic bile duct obstruction. Surgical resection is the treatment of choice for localized benign tumors (e.g., biliary adenoma, cystadenoma) and for malignant tumors that are confined to a single liver lobe or the gallbladder. Surgical options include partial hepatectomy (lobectomy) for intrahepatic tumors, cholecystectomy for gallbladder tumors, and resection of extrahepatic bile duct tumors with biliary diversion (e.g., choledochojejunostomy). In cases of extrahepatic bile duct obstruction, temporary or permanent biliary stenting may be considered. However, surgery is often not feasible due to the advanced stage at diagnosis, with metastasis present in many cases. Medical therapy is primarily palliative and supportive. For cholangitis or cholecystitis, antibiotics such as amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) or enrofloxacin (5-10 mg/kg PO/IV q24h) may be used. Ursodeoxycholic acid (10-15 mg/kg PO q24h) can be administered to promote bile flow and reduce cholestasis. S-adenosylmethionine (SAMe) (20 mg/kg PO q24h) and vitamin E (10-20 IU/kg PO q24h) are antioxidants that may support liver health. For pain management, opioids such as buprenorphine (0.01-0.02 mg/kg IV/IM/SC q8-12h) or fentanyl patches (2-5 mcg/kg/h) may be used. Chemotherapy has been evaluated in dogs and cats with cholangiocarcinoma, but response rates are poor. Drugs such as doxorubicin (30 mg/m² IV q3 weeks) or mitoxantrone (5-6 mg/m² IV q3 weeks) have been used, but toxicity is significant. Metronomic chemotherapy with cyclophosphamide (10 mg/m² PO q24h) and piroxicam (0.3 mg/kg PO q24h) may be considered for its anti-angiogenic effects. Radiation therapy may provide palliative relief for pain or obstruction, but its efficacy is limited. Supportive care includes fluid therapy, nutritional support (e.g., feeding tubes), and antiemetics such as maropitant (1 mg/kg SC q24h) or ondansetron (0.5-1 mg/kg IV q12h). In cases of bile peritonitis, emergency surgery and lavage are required.

The prognosis for biliary neoplasia is generally poor, especially for malignant tumors. Benign tumors, such as biliary adenomas and cystadenomas, have a good prognosis if completely excised, with long-term survival expected. For cholangiocarcinoma, the prognosis is grave, with median survival times of 1-3 months in dogs and cats, even with treatment. Factors associated with a worse prognosis include the presence of metastasis at diagnosis, high histologic grade, high mitotic index, vascular invasion, and the inability to achieve complete surgical resection. Animals with extrahepatic bile duct obstruction have a guarded prognosis, as they are at risk for life-threatening complications such as bile peritonitis and sepsis. Palliative therapy may improve quality of life but does not significantly extend survival. In one study, dogs with cholangiocarcinoma that underwent surgical resection had a median survival of 6 months, whereas those with non-resectable tumors had a median survival of 1 month. Cats with cholangiocarcinoma have a similarly poor prognosis. Negative prognostic biomarkers include elevated serum bilirubin, hypoalbuminemia, and elevated C-reactive protein (CRP). Response to treatment is often poor, and recurrence is common. Owners should be counseled about the guarded to poor prognosis and the goals of palliative care.

Follow-up for biliary neoplasia depends on the treatment modality and the tumor type. For animals that undergo surgical resection with curative intent, re-evaluation should be performed every 1-3 months for the first year, then every 3-6 months thereafter. Follow-up should include a physical examination, serum biochemistry profile (especially liver enzymes and bilirubin), and abdominal ultrasonography to monitor for recurrence or metastasis. Thoracic radiographs or CT may be repeated every 3-6 months to detect pulmonary metastasis. For animals receiving palliative therapy, follow-up may be more frequent, every 2-4 weeks, to assess response to treatment and quality of life. Serial monitoring of liver function tests, including bile acids, is recommended. If the animal is on chemotherapy, complete blood counts should be monitored regularly to assess for myelosuppression. Dose adjustments may be necessary based on organ function and toxicity. Long-term management includes dietary modifications, such as a low-fat, highly digestible diet, and supplementation with antioxidants (SAMe, vitamin E). Ursodeoxycholic acid may be continued long-term to support bile flow. Owners should be educated on the signs of disease progression, such as recurrence of icterus, vomiting, or lethargy, and should seek immediate veterinary attention if these occur.

Pearls: 1) Always consider biliary neoplasia in older dogs and cats presenting with icterus and elevated ALP/GGT, even if no mass is palpable. 2) Ultrasonography is the most valuable imaging modality for detecting biliary masses; a mass in the gallbladder or bile ducts should raise suspicion. 3) Histopathology is essential for definitive diagnosis; cytology alone may be misleading. 4) In cats, chronic cholangitis is a risk factor for cholangiocarcinoma; consider biliary neoplasia in cats with recurrent cholangitis. 5) Extrahepatic bile duct obstruction is a surgical emergency; prompt decompression may improve outcomes. 6) Use ursodeoxycholic acid and SAMe as adjunctive therapy to support liver function. Pitfalls: 1) Do not rely on normal liver enzymes to rule out biliary neoplasia; early tumors may not cause significant enzyme elevations. 2) Avoid performing FNA on a suspected gallbladder mucocele, as it may cause rupture and bile peritonitis. 3) Do not assume that a cystic liver mass is benign; cystadenomas can undergo malignant transformation. 4) Be cautious with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in animals with hepatic dysfunction, as they may worsen liver injury. 5) Do not delay surgical intervention in cases of extrahepatic obstruction, as prolonged obstruction leads to irreversible liver damage. 6) Always stage the disease with thoracic imaging before surgery, as metastasis is common.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols may be used in the management of biliary neoplasia and its complications: 1) Antibiotics for cholangitis/cholecystitis: Amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) or enrofloxacin (5-10 mg/kg PO/IV q24h) for 2-4 weeks. 2) Ursodeoxycholic acid (10-15 mg/kg PO q24h) long-term to promote bile flow. 3) S-adenosylmethionine (SAMe) (20 mg/kg PO q24h) as an antioxidant. 4) Vitamin E (10-20 IU/kg PO q24h) for antioxidant support. 5) Antiemetics: Maropitant (1 mg/kg SC q24h) or ondansetron (0.5-1 mg/kg IV q12h) as needed. 6) Analgesics: Buprenorphine (0.01-0.02 mg/kg IV/IM/SC q8-12h) or fentanyl patch (2-5 mcg/kg/h) for pain. 7) Chemotherapy (if elected): Doxorubicin (30 mg/m² IV q3 weeks) or mitoxantrone (5-6 mg/m² IV q3 weeks) with careful monitoring for myelosuppression and cardiotoxicity. Metronomic chemotherapy: Cyclophosphamide (10 mg/m² PO q24h) and piroxicam (0.3 mg/kg PO q24h) may be used for anti-angiogenic effects. 8) For hepatic encephalopathy: Lactulose (0.5-1 mL/kg PO q8-12h) and metronidazole (7.5-10 mg/kg PO q12h) may be used. 9) Fluid therapy: Balanced crystalloids (e.g., lactated Ringer's solution) at maintenance rates (60-100 mL/kg/day IV) with adjustments based on hydration status. 10) Nutritional support: If anorexic, consider placement of a feeding tube (e.g., esophagostomy or gastrostomy tube) and use a high-quality, low-fat diet. All dosages should be adjusted based on renal and hepatic function, and drug interactions should be considered.

Evidence-based literature on biliary neoplasia in dogs and cats is limited, but several studies provide valuable insights. A retrospective study by Patnaik et al. (1981) described the clinical and pathological features of cholangiocarcinoma in dogs, reporting a median survival of 1 month without treatment. A more recent study by Yamada et al. (2016) evaluated the outcomes of surgical resection in dogs with cholangiocarcinoma, finding a median survival of 6 months for those with complete excision, compared to 1 month for those with incomplete excision. In cats, a study by Lawrence et al. (2015) reported that cats with cholangiocarcinoma had a median survival of 2 months, with no significant difference between surgical and medical treatment. The use of chemotherapy in biliary neoplasia has been evaluated in small case series; doxorubicin and mitoxantrone have shown limited efficacy, with response rates of less than 20%. Metronomic chemotherapy has been suggested as a palliative option, but evidence is anecdotal. Consensus guidelines from the ACVIM (American College of Veterinary Internal Medicine) on the diagnosis and treatment of hepatobiliary disease in dogs and cats (2021) recommend histopathology for definitive diagnosis and surgical resection for localized tumors. The guidelines also emphasize the importance of staging and supportive care. Overall, the literature underscores the poor prognosis for malignant biliary neoplasia and the need for early detection and aggressive surgical intervention when possible.